References
- Balani SK, Li P, Nguyen J, et al. (2004). Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. Drug Metab Dispos 32:1092–5
- Balani SK, Zhu T, Yang TJ, et al. (2002). Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab Dispos 30:1059–62
- Boily MO, Chauret N, Laterreur J, et al. (2015). In vitro and in vivo mechanistic studies toward understanding the role of 1-aminobenzotriazole in rat drug-drug interactions. Drug Metab Dispos 43:1960–5
- Caldwell GW, Ritchie DM, Masucci JA, et al. (2005). The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens. Eur J Drug Metab Pharmacokinet 30:75–83
- Capello S, Henderson L, DeGrazia F, et al. (1990). The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam. Drug Metab Dispos 18:190–6
- Dalmadi B, Leibinger J, Szeberenyi S, et al. (2003). Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos 31:631–6
- Furnes B, Schlenk D. (2005). Extrahepatic metabolism of carbamate and organophosphate thioether compounds by the flavin-containing monooxygenase and cytochrome P450 systems. Drug Metab Dispos 33:214–18
- Ho A, Chin A. (1988). Circadian feeding and drinking patterns of genetically obese mice fed solid chow diet. Physiol Behav 43:651–6
- Leong BK, Sabaitis CP, Rop DA, et al. (1997). Alterations in the cardiopulmonary effects and pharmacokinetics of a bisphosphonate drug by a cytochrome P-450 inhibitor in conscious rats. J Appl Toxicol 17:279–88
- Meschter CL, Mico BA, Mortillo M, et al. (1994). A 13-week toxicologic and pathologic evaluation of prolonged cytochromes P450 inhibition by 1-aminobenzotriazole in male rats. Fundam Appl Toxicol 22:369–81
- Muzeeb S, Pasha MK, Basha SJS, et al. (2005). Effect of 1-aminobenzotriazole on the in vitro metabolism and single-dose pharmacokinetics of chlorzoxazone, a selective CYP2E1 substrate in Wistar rats. Xenobiotica 35:825–38
- Parrish KE, Mao J, Chen J, et al. (2016). In vitro and in vivo characterization of CYP inhibition by 1-aminobenzotriazole in rats. Biopharm Drug Dispos 37:200–11
- Schulz-Utermoehl T, Spear M, Pollard CRJ, et al. (2010). In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. Drug Metab Dispos 38:1688–97
- Strelevitz TJ, Foti RS, Fisher MB. (2006). In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J Pharm Sci 95:1334–41
- Stringer RA, Ferreira S, Rose J, Ronseaux S. (2016). Application of osmotic pumps for sustained release of 1-aminobenzotriazole and inhibition of cytochrome p450 enzymes in mice: model comparison with the hepatic P450 reductase null mouse. Drug Metab Dispos 44:1213–6
- Stringer RA, Weber E, Culshaw A, et al. (2014a). Preclinical metabolism and pharmacokinetics of NVS-CRF38, a potent and orally bioavailable corticotropin-releasing factor receptor 1 antagonist. Xenobiotica 44:902–12
- Stringer RA, Weber E, Tigani B, et al. (2014b). 1-Aminobenzotriazole modulates oral drug pharmacokinetics through cytochrome P450 inhibition and delay of gastric emptying in rats. Drug Metab Dispos 42:1117–24
- Subramanian R, Aidasani D, Bailey K, et al. (2014). P450-mediated O-demethylated metabolite is responsible for rat hepatobiliary toxicity of pyridyltriazine-containing PI3K inhibitors. Toxicol Sci 142:298–310
- Watanabe A, Mayumi K, Nishimura K, Osaki H. (2016). In vivo use of the CYP inhibitor 1-aminobenzotriazole to increase long-term exposure in mice. Biopharm Drug Dispos 37:373–8
- Wityak J, McGee KF, Conlon MP, et al. (2015). Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors. J Med Chem 58:2967–87